Analysis of miR-143, miR-1, miR-210 and let-7e Expression in Colorectal Cancer in Relation to Histopathological Features.
RT-PCR
colorectal cancer
miRNA
Journal
Genes
ISSN: 2073-4425
Titre abrégé: Genes (Basel)
Pays: Switzerland
ID NLM: 101551097
Informations de publication
Date de publication:
13 05 2022
13 05 2022
Historique:
received:
12
04
2022
revised:
10
05
2022
accepted:
11
05
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
1
6
2022
Statut:
epublish
Résumé
MicroRNAs (miRNAs) are small RNA molecules involved in the control of the expression of many genes and are responsible for, among other things, cell death, differentiation and the control of their division. Changes in miRNA expression profiles have been observed in colorectal cancer. This discovery significantly enriches our knowledge of the pathogenesis of colorectal cancer and offers new goals in diagnostics and therapy. The aim of this study was to analyze the expression of four miRNA sequences-miR-143, miR-1, miR-210 and let-7e-and to investigate their significance in the risk of developing colorectal cancer. miRNA sequences were investigated in formalin-fixed, paraffin-embedded (FFPE) tissue in colorectal cancer patients ( This study revealed a lower expression of miR-143 in colorectal cancer patients than in the controls. miR-143 was positively correlated with the degree of tumor differentiation (grading). Three out of four analyzed miRNA (miR-1, miR-210 and let-7e) were found to be statistically insignificant in terms of colorectal carcinoma risk. miR-143 may be associated with the development of colorectal cancer.
Sections du résumé
BACKGROUND
MicroRNAs (miRNAs) are small RNA molecules involved in the control of the expression of many genes and are responsible for, among other things, cell death, differentiation and the control of their division. Changes in miRNA expression profiles have been observed in colorectal cancer. This discovery significantly enriches our knowledge of the pathogenesis of colorectal cancer and offers new goals in diagnostics and therapy.
AIM
The aim of this study was to analyze the expression of four miRNA sequences-miR-143, miR-1, miR-210 and let-7e-and to investigate their significance in the risk of developing colorectal cancer.
MATERIALS AND METHODS
miRNA sequences were investigated in formalin-fixed, paraffin-embedded (FFPE) tissue in colorectal cancer patients (
RESULTS
This study revealed a lower expression of miR-143 in colorectal cancer patients than in the controls. miR-143 was positively correlated with the degree of tumor differentiation (grading). Three out of four analyzed miRNA (miR-1, miR-210 and let-7e) were found to be statistically insignificant in terms of colorectal carcinoma risk.
CONCLUSIONS
miR-143 may be associated with the development of colorectal cancer.
Identifiants
pubmed: 35627259
pii: genes13050875
doi: 10.3390/genes13050875
pmc: PMC9141994
pii:
doi:
Substances chimiques
MIRN1 microRNA, human
0
MIRN143 microRNA, human
0
MIRN210 microRNA, human
0
MicroRNAs
0
mirnlet7 microRNA, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Cell Cycle. 2018;17(10):1212-1219
pubmed: 29886785
FEBS J. 2009 Nov;276(22):6689-700
pubmed: 19843160
Genome Med. 2016 Mar 17;8(1):29
pubmed: 26988859
Biochem Biophys Res Commun. 2014 Apr 18;446(4):1255-60
pubmed: 24690171
Oncol Rep. 2018 Aug;40(2):589-598
pubmed: 29845255
J Hum Genet. 2014 Feb;59(2):78-87
pubmed: 24284362
J Cell Physiol. 2009 Aug;220(2):485-91
pubmed: 19391107
Cancer Control. 2019 Jan-Dec;26(1):1073274819862784
pubmed: 31431043
Oncotarget. 2014 Jul 30;5(14):5416-27
pubmed: 24980823
Cancer Gene Ther. 2010 Jun;17(6):398-408
pubmed: 20094072
Nucleic Acids Res. 2012 Jan;40(2):761-74
pubmed: 21917858
BMC Cancer. 2015 Dec 29;15:1024
pubmed: 26714641
Biotechnol Appl Biochem. 2021 Sep 22;:
pubmed: 34550619
Cancer Res. 2011 Aug 1;71(15):5214-24
pubmed: 21690566
Cancer Lett. 2013 Jan 28;328(2):353-61
pubmed: 23104321
Cancer Cell Int. 2016 Jun 10;16:42
pubmed: 27293381
Mol Cancer. 2010 Aug 06;9:211
pubmed: 20687965
Anticancer Res. 2016 Mar;36(3):1093-102
pubmed: 26977004
Cancer Cell Int. 2015 Sep 29;15:92
pubmed: 26425114
Mol Cancer Res. 2003 Oct;1(12):882-91
pubmed: 14573789
Br J Cancer. 2009 Aug 18;101(4):699-706
pubmed: 19638978
Carcinogenesis. 2015 May;36(5):528-37
pubmed: 25804644
BMC Cancer. 2012 Jan 20;12:29
pubmed: 22260523
J Pharmacol Sci. 2010;114(3):276-80
pubmed: 20953119
Gastroenterology. 2020 Jan;158(2):418-432
pubmed: 31394083
J Cell Physiol. 2019 Jul;234(7):10718-10725
pubmed: 30515804
Methods Mol Biol. 2017;1509:17-24
pubmed: 27826914
Arch Iran Med. 2017 Feb;20(2):92-95
pubmed: 28193082
Aging (Albany NY). 2021 Aug 13;13(15):19894-19907
pubmed: 34388112
Leuk Res. 2009 Nov;33(11):1530-8
pubmed: 19464056
J Cell Mol Med. 2019 May;23(5):3050-3057
pubmed: 30801950
Oncogene. 2013 Oct;32(40):4806-13
pubmed: 23128394
Cancer Discov. 2016 Feb;6(2):188-201
pubmed: 26586766
Hepatology. 2009 Jun;49(6):1935-43
pubmed: 19475691
Biomed Pharmacother. 2020 Dec;132:110903
pubmed: 33096351
Oncotarget. 2017 Jan 24;8(4):6970-6983
pubmed: 28036302
PLoS One. 2010 Jan 21;5(1):e8836
pubmed: 20098684
Int J Oncol. 2015 Feb;46(2):750-6
pubmed: 25385144
J Pers Med. 2022 Mar 14;12(3):
pubmed: 35330456
PLoS One. 2021 Apr 26;16(4):e0249238
pubmed: 33901189
Cancer Lett. 2011 Aug 28;307(2):211-20
pubmed: 21550168
Cancer Lett. 2013 Jul 28;335(2):332-42
pubmed: 23499891
Tumour Biol. 2014 Apr;35(4):2983-8
pubmed: 24248543
Oncotarget. 2017 Jun 27;8(26):42043-42060
pubmed: 28159933
Rep Biochem Mol Biol. 2021 Jan;9(4):408-416
pubmed: 33969134
Nature. 2005 Jun 9;435(7043):834-8
pubmed: 15944708
Hum Antibodies. 2020;28(4):273-285
pubmed: 32623393
Cell Cycle. 2012 Jun 1;11(11):2137-45
pubmed: 22592534
Biomed Pharmacother. 2017 Nov;95:1314-1320
pubmed: 28938522
Pharmaceuticals (Basel). 2021 Feb 08;14(2):
pubmed: 33567635
Acta Biochim Biophys Sin (Shanghai). 2012 May;44(5):407-14
pubmed: 22472569
Cancer Lett. 2013 Jul 28;335(2):455-62
pubmed: 23499894
J Cell Physiol. 2018 Feb;233(2):901-913
pubmed: 28092102
Cell Cycle. 2013 May 1;12(9):1385-94
pubmed: 23574723
Arq Gastroenterol. 2020 Apr-Jun;57(2):172-177
pubmed: 33206858
Mol Med Rep. 2012 Mar;5(3):753-60
pubmed: 22160209
Expert Rev Proteomics. 2019 Oct;16(10):851-856
pubmed: 31446809
Endocr Relat Cancer. 2014 Aug;21(4):517-31
pubmed: 24781864
Clin Epigenetics. 2017 Feb 14;9:22
pubmed: 28289479
Cancer Genomics Proteomics. 2009 Jul-Aug;6(4):195-204
pubmed: 19656996
Mol Cancer. 2012 Apr 25;11:23
pubmed: 22533346
Biomed Pharmacother. 2021 Feb;134:111099
pubmed: 33338745
Mol Cancer. 2013 Jul 17;12:77
pubmed: 23866094
PLoS One. 2014 Dec 04;9(12):e114420
pubmed: 25474488
Cancer Epidemiol Biomarkers Prev. 2011 Jul;20(7):1272-86
pubmed: 21551242
Biomed Res Int. 2021 Aug 11;2021:7703159
pubmed: 34423038